Cholinergic drugs for alzheimer's disease enhance in vitro dopamine release

Molecular Pharmacology

Volumn 66, Issue 3, 2004, Pages 538-544

  Zhang, Lifen ^a   Zhou, Fu Ming ^a   Dani, John A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBENONIUM; ATROPINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIHYDRO BETA ERYTHROIDINE; DONEPEZIL; DOPAMINE; GALANTAMINE;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; CYCLIC POTENTIOMETRY; DOPAMINE RELEASE; DRUG MECHANISM; ELECTROSTIMULATION; MOUSE; NERVE POTENTIAL; NONHUMAN; PRIORITY JOURNAL;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; CHOLINERGIC AGENTS; CHOLINESTERASE INHIBITORS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GALANTAMINE; INDANS; MICE; PIPERIDINES; RECEPTORS, NICOTINIC;

EID: 4944239612     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.000299     Document Type: Article

References (52)

1. Albuquerque EX, Alkondon M, Pereira EF, Castro NG, Schrattenholz A, Barbosa CT, Bonfante-Cabarcas R, Aracava Y, Eisenberg HM, and Maelicke A (1997) Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 280:1117-1136.
2. Aosaki T, Kimura M, and Graybiel AM (1995) Temporal and spatial characteristics of tonically active neurons of the primate's striatum. J Neurophysiol 73:1234-1252.
3. Assal F and Cummings JL (2002) Neuropsychiatric symptoms in the dementias. Curr Opin Neurol 15:445-450.
4. Barnes CA, Meltzer J, Houston F, Orr G, McGann K, and Wenk GL (2000) Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 99:17-23.
5. Bennett BD and Wilson CJ (1999) Spontaneous activity of neostriatal cholinergic interneurons in vitro. J Neurosci 19:5586-5596.
6. Björklund A and Lindvall O (1984) Dopamine-containing systems in the CNS, in Classical Transmitters in the CNS, Part I (Björklund A, Hökfelt T eds) pp 55-122, Elsevier, Amsterdam.
7. Blesa R (2000) Galantamine: therapeutic effects beyond cognition. Dement Geriatr Cogn Disord 11 Suppl 1:28-34.
8. Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, Rush DK, Selk DE, Wolf V, Kosley RW Jr, Davis L, et al. (1996) Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 277:728-738.
9. Butcher LL and Woolf NJ (1984) Histochemical distribution of acetylcholinesterase in the central nervous system: clues to the localization of cholinergic neurons, in Classical Transmitters and Transmitter Receptors in the CNS (Björklund A, Hökfelt T, and Kuhar MJ eds) pp 1-50, Elsevier, Amsterdam.
10. Calabresi P, Centonze D, Gubellini P, Pisani A, and Bernardi G (2000) Acetylcholine-mediated modulation of striatal function. Trends Neurosci 23:120-126.
11. Court JA, Piggott MA, Lloyd S, Cookson N, Ballard CG, McKeith IG, Perry RH, and Perry EK (2000) Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Neuroscience 98:79-87.
12. Coyle JT, Price DL, and DeLong MR (1983) Alzheimer's disease: a disorder of cortical cholinergic innervation. Science (Wash DC) 219:1184-1190.
13. 2+ signals and neurotransmitter release. Mol Pharmacol 64:1217-1226.
14. Dani JA (2001) Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry 49:166-174.
15. Erkinjuntti T (2002) Treatment options: the latest evidence with galantamine (Reminyl). J Neurol Sci 203-204:125-130.
16. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, and Whalen E (2001) A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57:613-620.
17. Fibiger HC (1991) Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends Neurosci 14:220-223.
18. Galvin JE, Lee VM, and Trojanowski JQ (2001) Synucleinopathies: clinical and pathological implications. Arch Neurol 58:186-190.
19. Grady SR, Meinerz NM, Cao J, Reynolds AM, Picciotto MR, Changeux JP, McIntosh JM, Marks MJ, and Collins AC (2001) Nicotinic agonists stimulate acetylcholine release from mouse interpeduncular nucleus: a function mediated by a different nAChR than dopamine release from striatum. J Neurochem 76:258-268.
20. Hill JA Jr, Zoli M, Bourgeois JP, and Changeux JP (1993) Immunocytochemical localization of a neuronal nicotinic receptor: the β2-subunit. J Neurosci 13:1551-1568.
21. Hodge AS, Humphrey DR, and Rosenberry TL (1992) Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities. Mol Pharmacol 41:937-942.
22. Johnson JH, Zhao C, James JR, and Rosecrans JA (2000) Individual variability of dopamine release from nucleus accumbens induced by nicotine. Brain Res Bull 51:249-253.
23. Jones IW, Bolam JP, and Wonnacott S (2001) Presynaptic localisation of the nicotinic acetylcholine receptor beta2 subunit immunoreactivity in rat nigrostriatal dopaminergic neurones. J Comp Neurol 439:235-247.
24. Joyce JN, Murray AM, Hurtig HI, Gottlieb GL, and Trojanowski J (1998) Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease. Neuropsychopharmacology 19:472-480.
25. Lilienfeld S (2002) Galantamine - a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev 8:159-176.
26. Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, and Breitner JC (2001) Neuropsychiatrie disturbance in Alzheimer's disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry 16:1043-1053.
27. Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, and Zerlin M (2001) Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 49:279-288.
28. Maelicke A, Schrattenholz A, Samochocki M, Radina M, and Albuquerque EX (2000) Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 113:199-206.
29. Mannens GS, Snel CA, Hendrickx J, Verhaeghe T, Le Jeune L, Bode W, van Beijsterveldt L, Lavrijsen K, Leempoels J, Van Osselaer N, et al. (2002) The metabolism and excretion of galantamine in rats, dogs and humans. Drug Metab Dispos 30:553-563.
30. Marshall DL, Redfern PH, and Wonnacott S (1997) Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J Neurochem 68:1511-1519.
31. McGehee DS and Role LW (1996) Presynaptic ionotropic receptors. Curr Opin Neurobiol 6:342-349.
32. Mulugeta E, Karlsson E, Islam A, Kalaria R, Mangat H, Winblad B, and Adem A (2003) Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients. Brain Res 960:259-262.
33. Nordberg A (1999) PET studies and cholinergic therapy in Alzheimer's disease. Rev Neurol (Paris) 155 Suppl 4:853-63.
34. Ogura H, Kosasa T, Kuriya Y, and Yamanishi Y (2000) Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butvrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol 22:609-613.
35. Palmer AM (2002) Pharmacotherapy for Alzheimer's disease: progress and prospects. Trends Pharmacol Sci 23:426-433.
36. Paterson D and Nordberg A (2000) Neuronal nicotinic receptors in the human brain. Prog Neurobiol 61:75-111.
37. Perry E, Martin-Ruiz C, Lee M, Griffiths M, Johnson M, Piggott M, Haroutunian V, Buxbaum JD, Nasland J, Davis K, et al. (2000) Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 393:215-222.
38. Perry EK (1986) The cholinergic hypothesis - ten years on. Br Med Bull 42:63-69.
39. Role LW and Berg BK (1996) Nicotinic receptors in the development and modulation of CNS synapses. Neuron 16:1077-1085.
40. Samochocki M, Zerlin M, Jostock R, Groot Kormelink PJ, Luyten WH, Albuquerque EX, and Maelicke A (2000) Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChB. Acts Neurol Scand Suppl 176:68-73.
41. Santos MD, Alkondon M, Pereira EF, Aracava Y, Eisenberg HM, Maelicke A, and Albuquerque EX (2002) The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 61:1222-1234.
42. Sarter M and Bruno JP (1997) Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: a rational approach for the development of cognition enhancers. Behav Brain Res 83:7-14.
43. Tyrrell PJ, Sawle GV, Ibañez V, Bloomfield PM, Leenders KL, Frackowiak RS, and Rossor MN (1990) Clinical and positive emission tomographic studies in the extrapyramidal syndrome of dementia of the Alzheimer type. Arch Neurol 47:1318-1323.
44. Vinson PN and Justice JB Jr (1997) Effect of neostigmine on concentration and extraction fraction of acetylcholine using quantitative microdialysis. J Neurosci Methods 73:61-67.
45. Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, Livingston G, Ince P, McKeith IG, and Katona CL (2002) Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73:134-140.
46. Werber EA and Rabey JM (2001) The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 108:1319-1325.
47. Wonnacott S (1997) Presynaptic nicotinic ACh receptors. Trends Neurosci 20:92-98.
48. Woodruff-Pak DS, Lander C, and Geerts H (2002) Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev 8:405-426.
49. Woolf NJ (1991) Cholinergic systems in mammalian brain and spinal cord. Prog Neurobiol 37:475-524.
50. Zhou FM, Liang Y, and Dani JA (2001) Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nature Neurosci 4:1224-1229.
51. Zhou FM, Wilson CJ, and Dani JA (2002) Cholinergic interneuron characteristics and nicotinic properties in the striatum. J Neurobiol 53:590-605.
52. Zhou FM, Wilson CJ, and Dani JA (2003) Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist 9:23-36.